1910 Genetics is the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation. We integrate AI with three proprietary data streams – computational data, wet lab proxy biological data, and wet lab ground truth biological data – to deliver novel drug candidates and software solutions to leading pharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer. We are backed by leading investors including M12 - Microsoft's Venture Fund, Playground Global, Sam Altman, Y Combinator, FoundersX Ventures, Scientia Ventures, and many others.